Does the media refer more to SPRY or FATE?

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Fate Therapeutics. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.11 beat ARS Pharmaceuticals' score of 0.08 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, FATE or XNCR?

Xencor has higher revenue and earnings than Fate Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.32M 41.67 -$136.32M -$1.09 N/A Xencor $97.36M 11.49 -$91.92M -$2.29 N/A

Is FATE or XNCR more profitable?

Xencor has a net margin of -177.10% compared to Fate Therapeutics' net margin of -2,056.79%. Xencor's return on equity of -28.77% beat Fate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fate Therapeutics -2,056.79% -58.89% -39.39% Xencor -177.10% -28.77% -20.52%

Does the media favor CGEM or FATE?

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat Cullinan Therapeutics' score of 0.60 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BIOA or FATE?

In the previous week, BioAge Labs had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 5 mentions for BioAge Labs and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.11 beat BioAge Labs' score of 0.47 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FATE or DBVT?

In the previous week, Fate Therapeutics and Fate Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat DBV Technologies' score of 0.63 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fate Therapeutics (FATE) Competitors

$2.26 +0.16 (+7.52%)

As of 09:49 AM Eastern

Compare

FATE vs. SPRY, XNCR, CGEM, BIOA, and DBVT

Should you buy Fate Therapeutics stock or one of its competitors? MarketBeat compares Fate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fate Therapeutics include ARS Pharmaceuticals (SPRY), Xencor (XNCR), Cullinan Therapeutics (CGEM), BioAge Labs (BIOA), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

How does Fate Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Fate Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.63	-$171.30M	-$2.01	N/A
Fate Therapeutics	$6.32M	41.67	-$136.32M	-$1.09	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ARS Pharmaceuticals presently has a consensus price target of $28.20, suggesting a potential upside of 245.00%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 126.97%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Fate Therapeutics. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.11 beat ARS Pharmaceuticals' score of 0.08 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals has a net margin of -200.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

Summary

Fate Therapeutics beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Xencor?

Fate Therapeutics (NASDAQ:FATE) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Xencor has higher revenue and earnings than Fate Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.32M	41.67	-$136.32M	-$1.09	N/A
Xencor	$97.36M	11.49	-$91.92M	-$2.29	N/A

Xencor has a net margin of -177.10% compared to Fate Therapeutics' net margin of -2,056.79%. Xencor's return on equity of -28.77% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Xencor	-177.10%	-28.77%	-20.52%

97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fate Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 126.97%. Xencor has a consensus target price of $24.50, indicating a potential upside of 62.34%. Given Fate Therapeutics' higher probable upside, research analysts clearly believe Fate Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, Fate Therapeutics had 2 more articles in the media than Xencor. MarketBeat recorded 3 mentions for Fate Therapeutics and 1 mentions for Xencor. Xencor's average media sentiment score of 1.87 beat Fate Therapeutics' score of 1.11 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
Fate Therapeutics	Positive
Xencor	Very Positive

Summary

Xencor beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat Cullinan Therapeutics' score of 0.60 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics currently has a consensus price target of $32.00, indicating a potential upside of 72.06%. Fate Therapeutics has a consensus price target of $5.13, indicating a potential upside of 126.97%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Cullinan Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Cullinan Therapeutics' return on equity of -51.45% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Fate Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Fate Therapeutics	$6.32M	41.67	-$136.32M	-$1.09	N/A

Summary

Fate Therapeutics beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Fate Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

BioAge Labs has a net margin of -871.75% compared to Fate Therapeutics' net margin of -2,056.79%. BioAge Labs' return on equity of -29.40% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

BioAge Labs has higher revenue and earnings than Fate Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	102.56	-$80.61M	-$2.40	N/A
Fate Therapeutics	$6.32M	41.67	-$136.32M	-$1.09	N/A

BioAge Labs presently has a consensus price target of $43.50, suggesting a potential upside of 82.77%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 126.97%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

97.5% of Fate Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BioAge Labs had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 5 mentions for BioAge Labs and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.11 beat BioAge Labs' score of 0.47 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

Summary

BioAge Labs beats Fate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to DBV Technologies?

Fate Therapeutics (NASDAQ:FATE) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

In the previous week, Fate Therapeutics and Fate Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat DBV Technologies' score of 0.63 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Fate Therapeutics has a net margin of -2,056.79% compared to DBV Technologies' net margin of -2,895.37%. Fate Therapeutics' return on equity of -58.89% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Fate Therapeutics currently has a consensus price target of $5.13, suggesting a potential upside of 126.97%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 181.49%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts clearly believe DBV Technologies is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fate Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.32M	41.67	-$136.32M	-$1.09	N/A
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

Summary

Fate Therapeutics beats DBV Technologies on 11 of the 15 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$259.23M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.22%	2.66%	6.11%
P/E Ratio	-2.04	21.75	25.88	24.17
Price / Sales	41.67	332.75	550.12	99.13
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	1.25	8.31	10.76	6.38
Net Income	-$136.32M	$23.92M	$3.58B	$337.00M
7 Day Performance	5.02%	1.93%	1.93%	-0.23%
1 Month Performance	-20.49%	-0.41%	-0.23%	-1.40%
1 Year Performance	117.12%	65.22%	34.40%	27.76%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	3.1345 of 5 stars	$2.26 +7.5%	$5.13 +127.0%	+101.9%	$259.23M	$6.32M	N/A	550
SPRY ARS Pharmaceuticals	3.4215 of 5 stars	$9.98 +3.4%	$28.60 +186.6%	-53.1%	$958.28M	$84.28M	N/A	90	Positive News High Trading Volume
XNCR Xencor	2.0686 of 5 stars	$14.01 +10.8%	$24.50 +74.9%	+84.9%	$937.15M	$125.58M	N/A	280
CGEM Cullinan Therapeutics	2.6906 of 5 stars	$17.30 +15.1%	$32.00 +85.0%	+137.1%	$923.71M	N/A	N/A	30
BIOA BioAge Labs	2.5745 of 5 stars	$21.47 +3.4%	$43.50 +102.6%	N/A	$923.29M	$10.32M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. SPRY, XNCR, CGEM, BIOA, and DBVT

How does Fate Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Fate Therapeutics compare to Xencor?

Summary

How does Fate Therapeutics compare to Cullinan Therapeutics?

Summary

How does Fate Therapeutics compare to BioAge Labs?

Summary

How does Fate Therapeutics compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. SPRY, XNCR, CGEM, BIOA, and DBVT

How does Fate Therapeutics compare to ARS Pharmaceuticals?

Which has stronger earnings and valuation, SPRY or FATE?

Do institutionals & insiders hold more shares of SPRY or FATE?

Do analysts prefer SPRY or FATE?

Does the media refer more to SPRY or FATE?

Is SPRY or FATE more profitable?

Which has more volatility & risk, SPRY or FATE?

Summary

How does Fate Therapeutics compare to Xencor?

Which has preferable earnings & valuation, FATE or XNCR?

Is FATE or XNCR more profitable?

Do institutionals and insiders have more ownership in FATE or XNCR?

Do analysts rate FATE or XNCR?

Which has more volatility & risk, FATE or XNCR?

Does the media prefer FATE or XNCR?

Summary

How does Fate Therapeutics compare to Cullinan Therapeutics?

Do insiders & institutionals believe in CGEM or FATE?

Does the media favor CGEM or FATE?

Do analysts recommend CGEM or FATE?

Is CGEM or FATE more profitable?

Which has more volatility and risk, CGEM or FATE?

Which has stronger valuation and earnings, CGEM or FATE?

Summary

How does Fate Therapeutics compare to BioAge Labs?

Is BIOA or FATE more profitable?

Which has higher earnings and valuation, BIOA or FATE?

Do analysts rate BIOA or FATE?

Do insiders and institutionals have more ownership in BIOA or FATE?

Does the media refer more to BIOA or FATE?

Which has more volatility and risk, BIOA or FATE?

Summary

How does Fate Therapeutics compare to DBV Technologies?

Does the media prefer FATE or DBVT?

Which has more volatility and risk, FATE or DBVT?

Is FATE or DBVT more profitable?

Do analysts prefer FATE or DBVT?

Do institutionals and insiders hold more shares of FATE or DBVT?

Which has better earnings and valuation, FATE or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools